Our history



OncoDiag is a French biotechnology company based in Normandy at one hour from Paris and Rouen cities. The company is focused on developing of non-invasive diagnostic tests for early detection of cancers. Its lead product the Urotest (CE-IVD) is a urine test for diagnosis and surveillance of bladder cancer. The company's pipeline also includes the Colodiag in development for early detection of colorectal cancer.

The management is assumed by a highly qualified team, with complementary expertise and supported by a scientific advisory board representative of the health sector.

 




	
Executive management


Claude Hennion, Ph.D.

President and CEO

Dr. Claude Hennion is co-founder of OncoDiag and has more than 30 years of experience in the management of start-up and valorisation of innovation. Claude has a Ph.D. in Physics from Paris VI University.


Jean-Pierre Roperch, Ph.D.

Director of Research & Development

Dr. Jean-Pierre Roperch is co-founder of OncoDiag and has more than 20 years of experience developing  "In Vitro" Diagnostic in oncology. Jean-Pierre has a Ph.D. in Cellular and Molecular Biology from Paris VI University.

 


 Scientific advisory board


Pr. Olivier Cussenot, MD, Ph.D.

Director of Urologic

Oncology from 

Tenon hospital, Paris

Pr. Bernard Grandchamp, MD, Ph.D. 

Geneticist from Bichat hospital, Paris

Roberto Incitti, Ph.D.

Mathematician and biostatistician from KAUST University, Saudi Arabia



Pr. Hicham Mansour, Ph.D.

Molecular biologist from Oudja University, Morocco


News & events
November 2017 : CE Mark for URODIAG by autocertification
September 2018 : Angels Santé, BAdGE & Normandie Business Angels invested in OncoDiag